220 related articles for article (PubMed ID: 19821827)
41. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations.
Gerr H; Zimmermann M; Schrappe M; Dworzak M; Ludwig WD; Bradtke J; Moericke A; Schabath R; Creutzig U; Reinhardt D
Br J Haematol; 2010 Apr; 149(1):84-92. PubMed ID: 20085575
[TBL] [Abstract][Full Text] [Related]
42. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
[TBL] [Abstract][Full Text] [Related]
44. [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
Szpecht D; Derwich K; Wachowiak J; Konatkowska B; Dworacki G
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1041-4. PubMed ID: 19531823
[TBL] [Abstract][Full Text] [Related]
45. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
46. Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 protocol.
Kuchinskaya E; Heyman M; Nordgren A; Söderhäll S; Forestier E; Wehner P; Vettenranta K; Jonsson O; Wesenberg F; Sahlén S; Nordenskjöld M; Blennow E
Br J Haematol; 2011 Mar; 152(5):615-22. PubMed ID: 21241277
[TBL] [Abstract][Full Text] [Related]
47. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Lejhancova-Tousovska K; Zapletal O; Vytiskova S; Strbackova P; Sterba J
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):144-54. PubMed ID: 22227959
[TBL] [Abstract][Full Text] [Related]
48. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Paganin M; Grillo MF; Silvestri D; Scapinello G; Buldini B; Cazzaniga G; Biondi A; Valsecchi MG; Conter V; Te Kronnie G; Basso G
Br J Haematol; 2018 Sep; 182(5):705-711. PubMed ID: 29938780
[TBL] [Abstract][Full Text] [Related]
49. [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):26-8. PubMed ID: 19563031
[TBL] [Abstract][Full Text] [Related]
50. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000.
Schrappe M; Möricke A; Reiter A; Henze G; Welte K; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Gruhn B; Niemeyer C; Kremens B; Niggli F; Debatin KM; Ratei R; Stanulla M; Beier R; Cario G; Schrauder A; Zimmermann M
Klin Padiatr; 2013 May; 225 Suppl 1():S62-72. PubMed ID: 23700060
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.
Inukai T; Kiyokawa N; Campana D; Coustan-Smith E; Kikuchi A; Kobayashi M; Takahashi H; Koh K; Manabe A; Kumagai M; Ikuta K; Hayashi Y; Tsuchida M; Sugita K; Ohara A
Br J Haematol; 2012 Feb; 156(3):358-65. PubMed ID: 22128890
[TBL] [Abstract][Full Text] [Related]
52. Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia.
Su XY; Busson M; Della Valle V; Ballerini P; Dastugue N; Talmant P; Ferrando AA; Baudry-Bluteau D; Romana S; Berger R; Bernard OA
Genes Chromosomes Cancer; 2004 Nov; 41(3):243-9. PubMed ID: 15334547
[TBL] [Abstract][Full Text] [Related]
53. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Piatopoulou D; Avgeris M; Marmarinos A; Xagorari M; Baka M; Doganis D; Kossiva L; Scorilas A; Gourgiotis D
Br J Cancer; 2017 Sep; 117(6):801-812. PubMed ID: 28787435
[TBL] [Abstract][Full Text] [Related]
54. High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Reismüller B; Steiner M; Pichler H; Dworzak M; Urban C; Meister B; Schmitt K; Pötschger U; König M; Mann G; Haas OA; Attarbaschi A;
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27804199
[TBL] [Abstract][Full Text] [Related]
55. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.
Prucker C; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Haas OA; Gadner H; Mann G;
Leukemia; 2009 Jul; 23(7):1264-9. PubMed ID: 19212332
[TBL] [Abstract][Full Text] [Related]
56. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Lauten M; Matthias T; Stanulla M; Beger C; Welte K; Schrappe M
Leukemia; 2002 Aug; 16(8):1437-42. PubMed ID: 12145682
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of dose-adjusted Berlin-Frankfurt-Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma.
Xie Y; Zhang Y; Zheng W; Wang X; Lin N; Tu M; Ping L; Ying Z; Zhang C; Liu W; Deng L; Song Y; Zhu J
Med Oncol; 2015 Apr; 32(4):110. PubMed ID: 25752875
[TBL] [Abstract][Full Text] [Related]
58. Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Fuhrmann S; Schabath R; Möricke A; Zimmermann M; Kunz JB; Kulozik AE; Ludwig WD; Schrappe M; Karawajew L; Ratei R
Br J Haematol; 2018 Oct; 183(1):96-103. PubMed ID: 30028023
[TBL] [Abstract][Full Text] [Related]
59. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
Graux C; Stevens-Kroef M; Lafage M; Dastugue N; Harrison CJ; Mugneret F; Bahloula K; Struski S; Grégoire MJ; Nadal N; Lippert E; Taviaux S; Simons A; Kuiper RP; Moorman AV; Barber K; Bosly A; Michaux L; Vandenberghe P; Lahortiga I; De Keersmaecker K; Wlodarska I; Cools J; Hagemeijer A; Poirel HA; ;
Leukemia; 2009 Jan; 23(1):125-33. PubMed ID: 18923437
[TBL] [Abstract][Full Text] [Related]
60. Significance of HOX11L2/TLX3 expression in children with T-cell acute lymphoblastic leukemia treated on Children's Cancer Group protocols.
Gottardo NG; Jacoby PA; Sather HN; Reaman GH; Baker DL; Kees UR
Leukemia; 2005 Sep; 19(9):1705-8. PubMed ID: 15990867
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
